Boundless Bio, Inc. (BOLD )

Currency in USD Disclaimer
$2.51 -$0 (-0.04%)
Open 06/26/2026
$2.48
$2.6
$0.96
$1.68

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol BOLD
  • Company Boundless Bio, Inc.
  • Price $2.51
  • Changes Percentage -0.04
  • Change -0.0011
  • Day Low $2.48
  • Day High $2.6
  • Year High $1.68
  • Year Low $0.96
  • Market Cap $32,348,320
  • Price Avg 50 EMA (D) $1.39
  • Price Avg 200 EMA (D) $1.25
  • Exchange NASDAQ
  • Volume 134,365
  • Average Volume 218,170
  • Open $2.5
  • Previous Close $2.51
  • EPS -2.49
  • PE -0.58
  • Earnings Announcement 2026-08-04 04:00:00
  • Shares Outstanding $22,464,111

Company brief: BOUNDLESS BIO, INC. (BOLD )

  • Healthcare
  • Biotechnology
  • Mr. Zachary Hornby
  • N/A
  • 07-20-2016
  • US10170A1007

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.

BOLD Corporation News

Income Statement